Gut Microbiome Health

2'-Fucosyllactose (2'-FL) is the most abundant human milk oligosaccharide and is a well-characterized prebiotic that selectively promotes growth of Bifidobacterium and butyrate-producing bacteria. A PMC-indexed batch-culture fermentation study and open-label pilot trial in IBS and ulcerative colitis adults showed increased Bifidobacterium counts and SCFA production. A 2024 randomized clinical trial in formula-fed infants confirmed its bifidogenic effect.

Acacia gum is a well-characterized prebiotic that increases Bifidobacteria and Lactobacilli while inhibiting pathogenic Clostridium species. A human dose-response RCT confirmed prebiotic effects at 10 g/day, comparable to inulin. In vitro models using human fecal microbiota confirm significant bifidogenic effects and SCFA production.

Acemannan functions as a prebiotic substrate: it is fermented by colonic microbiota into short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. In vitro studies using human fecal cultures show selective stimulation of beneficial bacteria. This activity underpins its documented GI health effects.

Both whole cooked adzuki bean and its polyphenol-rich water extract significantly reverse HFD-induced gut microbiota dysbiosis in mice, increasing α-diversity, reducing the Firmicutes/Bacteroidetes ratio, and promoting Bifidobacterium. Dietary fiber from adzuki bean is fermented by gut microbiota to produce short-chain fatty acids. A ScienceDirect study also shows adzuki bean seed coat fiber and bound polyphenols ameliorate colitis markers.

Agar-derived oligosaccharides (agaro-oligosaccharides, agarotriose) have demonstrated prebiotic activity in vitro by selectively fermenting bifidobacteria and being degraded by gut Bacteroides species isolated from human feces. Human gut microbes capable of degrading agar polysaccharides have been identified in stool samples, establishing a biological interaction. In vitro and mechanistic evidence is strong, though human intervention trials specifically measuring microbiome shifts with agar are lacking.

Akkermansia muciniphila is a mucin-degrading commensal bacterium that plays a key role in gut barrier integrity, microbial diversity, and immune regulation. Metagenomic studies show its abundance is inversely correlated with metabolic disorders, IBD, and obesity. Preclinical and emerging clinical studies demonstrate therapeutic potential for improving gut microbiome composition, insulin sensitivity, and intestinal barrier function.

Alginate acts as a prebiotic substrate for select gut bacteria, promoting SCFA production (acetate, propionate, butyrate) and enriching beneficial microbes such as Bifidobacterium animalis. Human and animal data support compositional shifts in the microbiome following alginate supplementation. Its oligosaccharide derivatives (AOS) have been particularly studied.

Multiple human clinical trials and a systematic review (Oxford Academic, 2025) establish that regular almond consumption exerts prebiotic effects, increasing populations of Bifidobacterium, Lactobacillus, and Roseburia while suppressing pathogenic bacteria. Almonds also promote production of short-chain fatty acids, particularly butyrate, which supports gut barrier integrity.

Aloe vera polysaccharides, particularly acemannan, improve gut mucosal integrity and modulate gut microbiota composition. Acemannan is digested in the colon by microbes into short-chain fatty acids, conferring prebiotic-like benefits. Research also shows aloe may influence gut microbiota in type 2 diabetes models.

Animal studies in rats, mice, and minipigs show AGIQ selectively increases butyrate-producing commensal bacteria (particularly Kineothrix alysoides) and genus Akkermansia without broadly disrupting gut microbiome diversity. These microbiome changes are mechanistically linked to AGIQ's downstream effects on brain function and depression. Evidence is currently preclinical.

Amaranth fiber acts as a fermentable prebiotic substrate, stimulating beneficial gut bacteria and producing short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. An in vitro prebiotic assessment study confirmed amaranth's ability to modulate human fecal microbiota and SCFA profiles. Animal studies also showed increased beneficial gut bacteria with amaranth supplementation.

A mouse study found annatto tocotrienol supplementation significantly reversed high-fat diet-induced gut microbiome dysbiosis, decreasing Firmicutes (including Ruminococcus lactaris and Lachnospiraceae) and increasing Akkermansia muciniphila, with concurrent improvements in insulin sensitivity and inflammatory markers. This represents the first study linking annatto tocotrienol to gut microbiome modulation.

Apple pectin and polyphenols act as prebiotics, selectively promoting growth of beneficial gut bacteria including Faecalibacterium prausnitzii and bifidobacteria while increasing SCFA production. Multiple in vitro colonic models and human RCTs have confirmed microbiome-modulatory effects.

Animal studies show ACV powder restores gut microbiota diversity, enriching beneficial taxa such as Muribaculaceae and Akkermansia, and reverses high-fat-diet-induced dysbiosis. ACV's prebiotic fiber (pectin) and polyphenols may support beneficial bacteria. Human microbiome data are currently limited to in vitro and animal models.

Arabinogalactan is a soluble polysaccharide fiber, most commonly derived from larch trees, that functions as a prebiotic by selectively stimulating Bifidobacterium and Lactobacillus populations in the gut. It is fermented by colonic bacteria to produce short-chain fatty acids, particularly butyrate. Multiple in vitro and some human studies support its prebiotic classification.

Arabinoxylan is a non-starch polysaccharide found in cereal brans and psyllium that functions as a prebiotic, selectively stimulating Bifidobacterium and Lactobacillus. A 2024 systematic review and meta-analysis of 34 human interventional studies confirmed its prebiotic efficacy and SCFA-stimulating activity. It meets all hallmarks of a recognized dietary prebiotic.

Aronia melanocarpa polyphenols have been shown in human and animal studies to modulate gut microbial communities, including increasing beneficial bacteria and reducing pro-inflammatory markers in gut cell models. A double-blind RCT collecting 16S rRNA fecal microbial composition data found measurable microbiome shifts with 30 days of Aronia juice consumption.

Artichoke is a significant source of inulin-type fructans and fructooligosaccharides, classified as prebiotics. An in vitro SHIME model study with artichoke aqueous dry extract demonstrated bifidogenic effects and increased production of health-related microbial metabolites. Artichoke's choleretic action also promotes bile acids in the colon, supporting beneficial intestinal flora.

Asparagus roots and spears are a meaningful source of inulin-type fructooligosaccharides (FOS) that selectively feed beneficial gut bacteria such as Lactobacillus and Bifidobacterium. In vitro fermentation studies using a Human Gut Simulator have confirmed that asparagus powder alters microbial community composition and supports beneficial Ruminococcus species. A. officinalis fructans have been characterized as emerging prebiotics with composition comparable to commercial inulin sources.

Multiple preclinical studies demonstrate that dietary Aspergillus-derived protease, lipase, and cellulase preparations exert bifidogenic effects, markedly elevating Bifidobacterium and Lactobacillus in the gut. A. oryzae glycosylceramide has been identified as a prebiotic for Blautia coccoides in murine models. A. oryzae-derived beta-galactosidase also produces galacto-oligosaccharides with confirmed prebiotic activity.

Polysaccharides and volatile oils from Atractylodes macrocephala have been extensively studied for their prebiotic-like effects on gut microbiota in preclinical models, promoting beneficial taxa and suppressing pathogenic bacteria, and modulating short-chain fatty acid and tryptophan metabolite production.

B. clausii is specifically indicated for restoration of disrupted intestinal bacterial flora. Preclinical and clinical studies demonstrate it restores microbiome diversity after antibiotic-induced dysbiosis, promotes competitive exclusion of pathogens, enhances mucin production, and secretes bacteriocins. It transiently colonizes the gut and drives rebalancing of microbial communities.

Bacillus coagulans is a lactic acid-producing, spore-forming probiotic that modulates gut microbiota composition and has been evaluated in multiple randomized clinical trials for IBS, diarrhea, and gut health. It increases beneficial bacteria and SCFA production and demonstrates significant resilience in the GI tract due to its sporulation ability.

Bacillus subtilis is a spore-forming bacterium used as a probiotic that positively modulates gut microbiota composition. It inhibits colonization of pathogenic bacteria, restores intestinal epithelial barrier function, and modulates gut immune responses. Both preclinical and clinical data support its beneficial effects on the gut microbiome.

Bamboo shoot dietary fiber acts as a prebiotic, promoting gut microbial diversity and short-chain fatty acid (SCFA) production in animal models. Multiple PMC-indexed studies demonstrate that bamboo fiber modulates the gut microbiome, increases beneficial bacteria (Bacteroidetes, Muribaculaceae, Akkermansia), and reduces harmful species. Fermented bamboo shoots also harbor Lactobacillus strains with documented probiotic properties.

Green banana resistant starch acts as a prebiotic, selectively promoting Bifidobacterium and Akkermansia growth in clinical studies. A 2024 RCT showed green banana powder significantly altered gut microbiome composition and improved bowel movement frequency. Fermentation of banana resistant starch by colonic bacteria produces short-chain fatty acids supporting intestinal barrier integrity.

Baobab fruit pulp powder, rich in pectin-type polysaccharides (notably low-methoxylated homogalacturonan), has demonstrated prebiotic potential in validated in vitro human gut models. In 48-hour fecal batch incubations, baobab powder significantly stimulated production of acetate (+18.4 mM), propionate (+5.5 mM), and butyrate compared with no-substrate controls. A 2024 SHIME® simulator study confirmed that baobab fiber, alone and in combination with Arabic gum, modulated microbial diversity and specifically increased Bifidobacteriaceae and Faecalibacterium prausnitzii.

Multiple preclinical and emerging clinical studies demonstrate berberine from barberry reshapes the gut microbiota by increasing Bacteroidetes, Akkermansia, and SCFA-producing genera while reducing pathobionts. These microbiome changes are mechanistically linked to improvements in glucose metabolism, inflammation, and gut barrier function.

Barley β-glucan, resistant starch, and fructan act as prebiotics, selectively stimulating Prevotella, Bifidobacterium, and butyrate-producing bacteria. Multiple human RCTs demonstrate increased fecal SCFA and butyrate concentrations and beneficial microbiome compositional shifts following barley consumption.

Bee pollen contains dietary fibers, polyphenols, and probiotic-associated compounds that demonstrably modulate gut microbial composition in animal and in vitro models. Fermented bee pollen postbiotics increased Lactobacillus and Bifidobacterium while reducing pathogenic E. coli in a cardiovascular disease microbiota model.

Benegut is reported in clinical studies to increase beneficial gut bacteria and support a healthier gut microbiota balance. Rosmarinic acid, a standardized constituent, has been shown in a literature review to be metabolized by human gut bacteria and may exert prebiotic-like effects. Chronic consumption mechanistic modeling suggests microbiota modulation as a key pathway underlying GI discomfort relief.

Berberine is an isoquinoline alkaloid that significantly modulates gut microbiota composition, promoting beneficial bacteria such as Bifidobacterium and Lactobacillus while suppressing pathogenic species. Multiple clinical and preclinical studies confirm its gut microbiome-mediated mechanisms in metabolic and inflammatory conditions, including type 2 diabetes and IBD.

Beta-glucan is a well-characterized soluble fiber from oats, barley, and fungi that functions as a prebiotic by increasing Prevotella, Roseburia, and other SCFA-producing bacteria. Multiple human RCTs confirm its bifidogenic and butyrogenic effects and its capacity to increase fecal SCFA production, particularly propionate and butyrate.

Bifidobacteria are among the most extensively studied beneficial gut bacteria and are a cornerstone of probiotic science. They ferment prebiotics to produce SCFAs, inhibit pathogen colonization, modulate gut immune responses, and are inversely correlated with dysbiotic and inflammatory GI conditions. Dozens of RCTs support their role in gut microbiome health.

Bifidobacterium adolescentis is a human gut commensal that ferments dietary fibers including arabinoxylan and resistant starch, producing acetate and supporting cross-feeding of butyrate-producing bacteria. It has been identified as a keystone species linking prebiotic intake to SCFA production and microbiome composition improvements in adult humans.

Bifidobacterium animalis, particularly the subspecies lactis, is one of the most commercially studied probiotic strains with documented effects on gut microbiota composition, intestinal transit, and immune modulation. Numerous RCTs have validated its safety and ability to beneficially shift the gut microbial profile.

Bifidobacterium bifidum is a key probiotic species in both infant and adult gut microbiomes, with specialized capacity to degrade human milk oligosaccharides and mucin. It is associated with enhanced gut barrier function, reduced pathogen colonization, and immune modulation in clinical trials.

Bifidobacterium breve is a probiotic strain dominant in breastfed infant microbiomes with extensively documented effects on gut microbiota modulation, intestinal barrier integrity, and immune regulation in both infants and adults. Multiple RCTs confirm its bifidogenic and anti-inflammatory properties.

Bifidobacterium infantis (B. longum subsp. infantis) is the dominant probiotic species in breastfed infants, with unparalleled HMO-utilization capacity. It is the subject of extensive clinical research demonstrating its role in establishing a healthy infant gut microbiome and reducing gut dysbiosis linked to inflammatory conditions.

Bifidobacterium lactis is one of the most commercially studied probiotic species, with strong clinical evidence for modulating gut microbiota composition, improving stool consistency, enhancing intestinal barrier integrity, and reducing gut dysbiosis across multiple populations and conditions.

Bifidobacterium longum is among the best-studied probiotic species in the gut, demonstrating documented effects on gut microbiota composition, SCFA production, intestinal barrier function, and modulation of gut-brain axis signaling. It is effective in IBS, antibiotic-associated dysbiosis, and infant gut microbiome establishment.

Bile salts and the gut microbiome are bidirectionally interdependent: gut bacteria modify bile acids through deconjugation, dehydroxylation, and re-conjugation, while bile acids shape microbial community composition through antimicrobial and receptor-mediated signaling. IBD is associated with significantly reduced bile salt biotransformation gene abundance versus healthy controls. Secondary bile acid diversity is a marker of healthy microbiome function.

Research published in Evidence-Based Complementary and Alternative Medicine examined how black pepper (alongside turmeric, ginger, and long pepper) alters the gut microbiome composition. Black pepper promoted measurable shifts in gut bacteria associated with health, consistent with its 5,000+ year traditional use as a digestive herb in Ayurveda.

Black tea polyphenols selectively modulate the composition of gut microbiota, promoting beneficial bacterial species and reducing pathobionts. Clinical and preclinical research identifies promotion of Flavonifractor plautii and prebiotically active effects on Bifidobacterium and Lactobacillus populations. Colonic fermentation of black tea polyphenols generates bioactive metabolites.

Multiple human RCTs and animal studies demonstrate that walnut consumption positively modifies gut microbial communities, increasing butyrate-producing bacteria (Faecalibacterium, Roseburia) and reducing pro-inflammatory secondary bile acids. An in vitro digestion study of walnut green husk showed selective modulation of gut microbiota with inhibition of pro-inflammatory bacteria.

Blackberry fiber and polyphenols act as prebiotics, enriching beneficial bacteria (Bifidobacteria, Lactobacilli) and promoting microbial diversity. Blackberry anthocyanins are metabolized by gut bacteria into bioactive urolithins and other metabolites. Ellagic acid from blackberries selectively promotes Bacteroidetes and modulates Firmicutes in animal models.

Fucoidan and alginates from bladderwrack resist small-intestinal digestion and reach the colon intact, where they selectively ferment to support beneficial bacteria and short-chain fatty acid production. Preclinical and in vitro human gut model data are available; bladderwrack-specific human trials are limited.

Blueberry polyphenols act as prebiotics, altering gut microbial composition and supporting growth of short-chain fatty acid-producing bacteria. Human RCT data confirm microbiome compositional changes, and gut-derived phenolic metabolites are established mediators of blueberry's systemic cardiometabolic effects.

Broccoli consumption alters human gastrointestinal microbiota composition, with clinical and preclinical studies documenting changes in Bacteroides species and other taxa. Broccoli fiber acts as a prebiotic substrate, while glucosinolates are bioactivated to isothiocyanates by gut bacteria — a two-way interaction between the plant compounds and the microbiome.

Brussels sprouts provide insoluble and soluble fiber that acts as a prebiotic substrate for beneficial gut bacteria. The raffinose oligosaccharides they contain are fermented in the colon, generating short-chain fatty acids that nourish colonocytes and modulate microbial composition. Their glucosinolates also interact with gut microbial metabolism.

Burdock root is a rich source of inulin (up to 50% of root dry weight), a well-established prebiotic that selectively stimulates beneficial gut bacteria. Animal studies using burdock root inulin (BRI) show increased intestinal microbiota diversity, reduced Firmicutes/Bacteroidota ratio, and enrichment of beneficial genera. A preclinical study (ScienceDirect, 2025) confirmed that BRI intervention altered gut microbiota composition and modulated lipid metabolism.

Tributyrin supplementation modulates gut microbiome composition, enriching beneficial bacteria while increasing luminal butyrate. A 2025 in vitro SHIME study using CoreBiome tributyrin showed enrichment of saccharolytic bacterial groups and metabolic shifts in the colonic environment. A 2024 human pilot study (ButyraGen, n=24) confirmed tolerability and SCFA-related microbiome changes. Tributyrin's pharmacokinetic advantage over sodium butyrate—resisting gastric acid and releasing butyrate via colonic lipases—supports its colonic microbiome effects.

Butyric acid is a short-chain fatty acid produced by colonic bacteria fermenting dietary fiber and is a primary energy substrate for colonocytes. It regulates intestinal barrier function, immune modulation, and gene expression, and is central to gut microbiome-host communication. Supplemental butyrate and its prodrug tributyrin are studied for gut microbiome and mucosal health.

Fermented cabbage (sauerkraut, kimchi) delivers live lactic acid bacteria and prebiotic fiber that modulate the gut microbiome. A 2018 clinical pilot RCT found lacto-fermented sauerkraut significantly improved IBS symptoms and altered gut microbiota composition. Animal studies show red cabbage juice enriches SCFA-producing bacteria and improves colonic barrier integrity.

A landmark 2019 mouse study published in Gut showed camu camu extract prevented obesity and shifted gut microbiota composition, notably increasing beneficial Akkermansia muciniphila. The 2024 Université Laval human RCT confirmed that camu camu supplementation also promoted gut microbiota composition changes in overweight, hypertriglyceridemic adults. These microbiome changes appear central to camu camu's metabolic benefits.

Caprylic acid is naturally produced in the gut by anaerobic microbial fermentation and is found at lower levels in IBD patients compared to healthy controls, suggesting it is a marker of a healthy microbiome. In vitro and animal data show antimicrobial selectivity against pathogens including Candida, while preclinical MCT studies show increases in beneficial Akkermansia. Human interventional data are limited.

Capsanthin extract significantly increased gut microbial diversity and altered microbiome composition in high-fat-diet mice, with concurrent reductions in serum TMAO—a microbiota-derived cardiovascular risk metabolite. These findings suggest capsanthin can modulate the gut microbial ecosystem.

Carrot-derived rhamnogalacturonan-I (cRG-I), a non-digestible pectic polysaccharide, acts as a prebiotic, selectively stimulating Bacteroides and Prevotella species and increasing short-chain fatty acid (SCFA) production. Multiple in vitro and simulated gut studies consistently demonstrate prebiotic activity.

Catechins modulate gut microbiota composition, promoting beneficial butyrate-producing bacteria and reducing potentially pathogenic species. Clinical and preclinical studies link catechin consumption to favorable shifts in microbial diversity, reduced dysbiosis, and improved gut-liver metabolic axis signaling.

Cowpea polyphenols and soluble fibers act as prebiotics and modulate gut microbial populations. An in vivo study in Gallus gallus found that zinc-biofortified cowpea extracts reduced abundance of Clostridium and E. coli. Cowpea bioactives also support short-chain fatty acid production during gut fermentation.

Cauliflower provides insoluble dietary fiber that acts as substrate for beneficial gut bacteria, promoting short-chain fatty acid (SCFA) production and microbiome diversity. Its glucosinolate compounds also reduce gut inflammation. Human dietary fiber intervention trials confirm modulation of microbiota composition and SCFA metabolism.

Cellulose digestion in the human gut is mediated partly by cellulase-producing bacteria such as ruminococcal species. Research published in Science (2024) identified three bacteria in the human gut microbiome capable of assembling cellulase complexes to degrade plant cell wall polysaccharides. Cellulase activity, whether endogenous or supplemental, influences SCFA production and microbial community composition. A pig model study (J Agric Food Chem, 2021) showed cellulase treatment significantly increased SCFA production and shifted carbohydrate metabolism pathways in gut microbiota.

A. bisporus polysaccharides (ABP) act as a prebiotic substrate in human gut fermentation, selectively enriching Bacteroides, Bifidobacterium, and Clostridiales and increasing short-chain fatty acid (SCFA) production. Champignon extract clinical trials also showed significant reductions in intestinal putrefaction products (ammonia, p-cresol, indole), indicating a favorable shift in gut microbial metabolism.

Multiple preclinical and one pilot human-model study show Chen Pi reshapes gut microbial communities, increasing beneficial short-chain fatty acid-producing bacteria and reducing dysbiosis-related metabolites. A 2025 RCT using Chenpi fermented enzyme drink demonstrated microbiome changes alongside lipid improvement in dyslipidaemic subjects.

Chia mucilage acts as a prebiotic substrate fermented by colonic bacteria, increasing populations of Lactobacillus and Enterococcus and stimulating short-chain fatty acid (SCFA) production. In vitro and preclinical data support this; direct human RCTs are limited.

Chickpea fibre and protein serve as prebiotic substrates, fermenting in the colon to produce SCFAs and selectively enriching beneficial microbial populations. Preclinical studies show chickpea-supplemented diets alter gut microbiome composition and enhance gut barrier integrity. A registered human RCT is actively evaluating 8 weeks of chickpea intake on microbiome diversity, metabolome, and gut barrier function.

Chicory root is the richest natural source of inulin-type fructans (FOS and inulin), which are among the most rigorously characterized prebiotics. Chicory inulin has been shown in multiple RCTs to selectively stimulate Bifidobacterium and Lactobacillus, improve stool frequency, and modulate gut microbiota composition.

Chlorella is a green microalgae dietary supplement with documented gut microbiota-modulating properties, promoting Lactobacillus and Bifidobacterium while reducing pathogenic bacteria. Polysaccharide components of Chlorella function as prebiotic substrates, and preclinical and limited human studies support its gut microbiome-relevant effects.

Oral chlorophyllin has been shown in mouse models to rebalance dysbiotic gut microbiota, specifically downregulating the Firmicutes phylum and upregulating Bacteroidetes, a compositional shift associated with improved metabolic and inflammatory health. This microbiota modulation was linked to attenuation of intestinal and hepatic inflammation. Human microbiome trials are lacking, but the animal mechanistic data is published in peer-reviewed literature.

A randomised controlled trial found that aronia polyphenol consumption significantly increased gut microbiome gene richness and abundance of butyrate-producing species. A 2024 British Journal of Nutrition systematic review of 57 human and animal studies confirmed that chokeberry polyphenols can modulate intestinal microbiota composition and exert downstream metabolic effects.

Citrus pectin acts as a prebiotic, selectively increasing Bifidobacterium, Lactobacillus, and Akkermansia muciniphila while reducing potentially pathogenic bacteria. Human trials confirm significant increases in fecal bifidobacteria. A 24-study systematic review confirms fragments selectively promote beneficial bacterial growth. These changes drive SCFA production benefiting the entire gut ecosystem.

Human clinical trials show that cocoa flavanol consumption modulates gut microbiota composition, significantly increasing beneficial Bifidobacterium and Lactobacillus populations while reducing pathogenic Clostridium species. Cocoa polyphenols act as prebiotics, interacting bidirectionally with gut bacteria.

Coconut milk's MCFAs, particularly lauric acid, exert selective antimicrobial effects against pathogenic bacteria and Candida in the gut while being free of lactose. Animal data show MCTs from coconut oil increase beneficial Akkermansia abundance and reduce intestinal permeability. Additive-free coconut milk is documented as gut-friendly for individuals intolerant to dairy.

Multiple preclinical studies demonstrate that coix seed polysaccharides and extracts significantly modulate gut microbiota composition, increasing diversity and beneficial SCFA-producing bacteria while reducing pathogenic genera, with downstream effects on metabolic health.

The insoluble fiber in collard greens acts as a prebiotic, feeding beneficial gut bacteria such as Agathobacter rectalis and stimulating production of short-chain fatty acids (SCFAs) including butyrate. Collards also contain sulfoquinovose — a sulfur-containing sugar with prebiotic properties — and glucoraphanin, which may protect the stomach lining. Glucosinolate-derived isothiocyanates have anti-inflammatory effects on gut tissue.

Bovine colostrum contains immunoglobulins (primarily IgG), lactoferrin, growth factors, and oligosaccharides that collectively support gut microbiome health by inhibiting pathogen adhesion, enhancing gut barrier integrity, and promoting beneficial bacterial colonization. Clinical studies in humans show gut microbiome-relevant effects particularly in diarrhea and gut permeability.

Multiple animal studies and mechanistic human research demonstrate that berberine from Coptis chinensis modulates gut microbiota composition, increasing beneficial species such as Akkermansia muciniphila while reducing pathogenic bacteria. These microbiome shifts are linked to its metabolic, anti-inflammatory, and intestinal barrier effects.

Soluble corn fiber (SCF) is a scientifically validated prebiotic that selectively enriches beneficial gut bacteria in human clinical studies. A double-blind RCT (n=24) found SCF dose-dependently increased Bifidobacterium counts. SCF also stimulates SCFA production by gut microbiota, with well-documented beneficial effects on gut ecology.

Cranberry polyphenols and oligosaccharides reach the colon largely unmetabolized and interact with gut microbiota. Clinical studies in humans show cranberry extract can increase Bifidobacterium and butyrate-producing bacteria. The evidence base is growing but still limited in size and duration. Prebiotic oligosaccharides in cranberry appear to contribute alongside polyphenols.

Curcumin is the principal bioactive in turmeric with extensively documented gut microbiota-modulating properties, including promoting beneficial bacteria, reducing pathogenic species, and increasing SCFA production. Multiple preclinical and clinical studies confirm its bidirectional interaction with gut microbiota, where gut bacteria also transform curcumin into bioactive metabolites.

Beta-glucuronidase—the colonic microfloral enzyme inhibited by D-glucarate—is a direct product of gut bacterial populations. Dysbiosis increases beta-glucuronidase output, driving enterohepatic recirculation of toxins and estrogens; D-glucarate inhibition of this enzyme functionally modulates this microbiome-liver axis. Evidence is mechanistic and biochemical, with human studies limited.

Dandelion root is a significant source of inulin, a well-characterized prebiotic fiber. Inulin selectively promotes Bifidobacterium and Lactobacillus growth and generates short-chain fatty acids. A controlled study showed dandelion polysaccharides were more effective than commercial inulin in promoting Lactobacillus rhamnosus. Human inulin data are extensive, though dandelion-specific human trials are limited.

DHA supplementation modulates gut microbiota composition, increasing beneficial bacteria and promoting metabolic pathways linked to carbohydrate and energy metabolism. Maternal DHA supplementation during lactation alters offspring gut microbiome. DHA's gut microbiome effects may mediate some of its neurological benefits via the gut-brain axis.

DPA supplementation has been shown to increase gut microbiota diversity and alter microbial composition in a mouse model of ulcerative colitis, promoting beneficial genera including Akkermansia, Lactobacillus, and Butyricicoccus. DPA also modifies fecal metabolite profiles, including upregulation of butyrate. Evidence is currently limited to preclinical models.

Dulse contains xylan as its primary structural polysaccharide; this fiber passes through the upper gut intact and acts as a prebiotic substrate for beneficial gut bacteria. In a mouse model, Palmaria palmata aqueous extract modulated gut microbiome community composition, increasing beneficial Lactobacillus populations and short-chain fatty acid (SCFA) production. These findings support dulse's role as a functional prebiotic.

EGCG, the major polyphenol in green tea, modulates gut microbiota by inhibiting potentially harmful Bacteroidetes and Firmicutes while preserving Lactobacillus, and by being extensively biotransformed by gut bacteria into bioactive metabolites. Multiple studies document its bidirectional gut microbiome interactions.

Elecampane root contains up to 44% inulin, a prebiotic fructooligosaccharide with robust clinical evidence for selectively promoting beneficial gut bacteria including Bifidobacterium and Lactobacillus species. Clinical trials of inulin supplementation support microbiome modulation, though trials using elecampane root directly are absent.

Fava beans provide resistant starch, soluble fiber (including galacto-oligosaccharides), and polyphenols that are fermented by colonic bacteria into short-chain fatty acids (SCFAs) including butyrate. A 2025 human dietary intervention found beneficial modulation of specific gut bacterial populations and metabolites after a 7-day fava bean-rich diet.

Gut microbial ferulic acid esterases (FAE) are critical enzymes that release ferulic acid from cereal conjugates in the colon, and FA's bioavailability depends on the diversity of FAE-producing microbiota. FA in turn modulates microbiota-related inflammatory and metabolic pathways. A 2025 MDPI review confirmed FA modulates 'microbiota-related pathways' as part of its MetS activity.

In a mouse model of Parkinson's disease, fisetin significantly altered gut microbiota composition, increasing beneficial Lachnospiraceae and reducing pathogenic Escherichia-Shigella species. This microbiota modulation was associated with neuroprotective outcomes via the gut-brain axis.

Flaxseed's mucilage fiber acts as a prebiotic, and clinical evidence shows supplementation alters gut microbiota composition. A randomized trial demonstrated changes in 33 metagenomic bacterial species following 6 weeks of flaxseed mucilage, alongside improved insulin sensitivity.

Fructooligosaccharides are established prebiotics with one of the strongest evidence bases for selectively promoting Bifidobacterium and Lactobacillus in the gut. A systematic review of 26+ human RCTs confirms their bifidogenic and butyrogenic effects, and they are EFSA- and ISAPP-recognized prebiotics.

Multiple in vitro fecal fermentation studies demonstrate that Poria cocos polysaccharides act as prebiotics, significantly increasing Lactobacillus and Bifidobacterium while decreasing pathogenic taxa. SCFA production increases and gut microbiota diversity improves. These effects have been demonstrated using human fecal microbiota.

Fucoidan is a sulfated polysaccharide from brown seaweed with documented prebiotic activity and gut microbiota modulation capacity. Multiple in vitro and preclinical studies show it increases Bifidobacterium and Lactobacillus while inhibiting pathogens; emerging human studies confirm gut microbiome-modulating effects.

In vivo animal studies and one human clinical trial with humic acid show fulvic acid increases gut microbiota concentration and promotes beneficial bacterial species while inhibiting pathogens. It is also documented as a prebiotic-like substance in multiple preclinical models.

Galactooligosaccharides (GOS) are well-established prebiotics synthesized from lactose that selectively promote Bifidobacterium and Lactobacillus. They are incorporated into infant formulas as HMO analogs and are among the prebiotics with strongest evidence from human RCTs for gut microbiota modulation.

Preclinical studies show Ganoderma lucidum water extract reverses high-fat diet-induced gut dysbiosis, decreasing Firmicutes-to-Bacteroidetes ratios, reducing endotoxin-bearing Proteobacteria, and maintaining intestinal barrier integrity. Gut microbiota modulation also appears to mediate its sleep-promoting effects via serotonin.

Garbanzo beans are rich in fermentable fiber, resistant starch, and raffinose-family oligosaccharides that serve as prebiotic substrates for beneficial colonic bacteria. These substrates are metabolized to short-chain fatty acids (SCFAs), which modulate gut microbiome composition, support colonocyte function, and enhance gut barrier integrity. Both preclinical and cell-model studies support these effects.

Geniposide from Gardenia jasminoides is metabolized by intestinal bacteria into genipin, making the gut microbiome central to its bioavailability and pharmacological activity. GJE has been shown to modulate gut microbiota composition in T2DM and sleep-deprivation models, and to protect intestinal mucosal integrity by upregulating tight junction proteins and suppressing pro-inflammatory cytokines. These are preclinical findings.

Garlic contains significant quantities of fructooligosaccharides (FOS) and fructans that function as prebiotic substrates, selectively stimulating beneficial gut bacteria including Bifidobacterium and Lactobacillus. Its organosulfur compounds also exert direct antimicrobial effects in the gut. The dual prebiotic and antimicrobial character of whole garlic makes its net microbiome effect complex.

Garlic's fructan content acts as a prebiotic, supporting growth of beneficial gut bacteria including Lactobacillus and Clostridial species. Clinical evidence shows AGE supplementation for 3 months improved microbial richness and diversity in hypertensive subjects. Garlic's sulfur compounds also modulate gut microbial composition through antimicrobial and antioxidant actions.

The efficiency of small intestinal starch digestion by glucoamylase directly determines the quantity and type of carbohydrate substrate reaching the colon, which in turn shapes the composition and metabolic output of the gut microbiome. Insufficient glucoamylase activity increases colonic starch fermentation and may alter microbial community structure.

Glucomannan (konjac glucomannan) is a highly viscous soluble fiber from konjac root that exhibits prebiotic properties by supporting gut microbiome diversity and SCFA production. Human RCTs confirm it increases butyrate-producing bacteria and Bifidobacterium, and it is recognized among dietary fibers with gut microbiota-modulating activity.

LBP acts as a prebiotic, modulating gut microbiota composition and metabolite production. Animal studies demonstrate that dietary goji supplementation alters microbiota to prevent alcohol-induced liver injury, increase cecal butyrate, and maintain epithelial barrier integrity. Fecal microbiota transplant experiments confirmed gut microbiota as the causal mediator of goji's hepatoprotective effects.

Green tea polyphenols (catechins, EGCG) bidirectionally interact with gut microbiota, being transformed by gut bacteria into bioactive metabolites while selectively modulating microbial community composition. Multiple human and preclinical studies confirm green tea promotes Lactobacillus and selectively inhibits pathogenic Firmicutes and Bacteroidetes.

Human and animal studies indicate that GLM extract may act as a prebiotic, modifying gut microbiota composition. A human study reported that 3 g/day whole GSM extract for 3 months reduced Clostridium and Staphylococcus species while increasing Lactobacillus, Streptococcus, Eubacterium, Bifidobacterium, and Enterococcus in the gut. A 2017 NIH-indexed review (PMC5532649) concluded that GLM extracts may exert prebiotic activity mediated by glycosaminoglycans and similar compounds providing substrate for beneficial bacteria.

Hemicellulase enzymatic activity generates hemicellulose-derived oligosaccharides (HDOs) such as xylooligosaccharides (XOS) and mannooligosaccharides (MOS), which function as emerging prebiotics selectively fermented by beneficial gut bacteria. Published peer-reviewed research in Frontiers in Nutrition (2021, PMC) confirms HDOs modulate microbiota composition favorably. Animal studies also show hemicellulose supplementation shifts microbiome beta-diversity and reduces obesogenic bacterial profiles.

Honey contains non-digestible oligosaccharides that may act as prebiotics, selectively promoting beneficial gut bacteria including bifidobacteria and lactobacilli. A 2022 Frontiers in Nutrition review (PMC9367972) summarizes in vitro, animal, and pilot human study evidence supporting honey's prebiotic capability. Evidence from controlled human trials is growing but still preliminary.

Honeysuckle-derived nanovesicles have been shown in preclinical murine models to increase beneficial gut bacteria, decrease pathogenic species, elevate short-chain fatty acids, and regulate bile acid metabolism. Honeysuckle MIR2911 (a plant miRNA) was identified as reducing Escherichia-Shigella abundance in colitis models by directly regulating gut bacteria.

A 2022 randomised human study demonstrated that 4-week daily consumption of H. italicum infusion significantly reduced serum IL-1β, IL-6, MCP-1, and zonulin, and produced a trend toward reducing Proteobacteria, suggesting prebiotic-like activity. The polyphenols in H. italicum are proposed to be fermented by gut microorganisms, modifying microbiome composition.

SBI has shown prebiotic-like effects on gut microbiota composition in human IBS/IBD patients and in ex vivo models. A 2024 PMC study found 30 days of SBI significantly increased species diversity, raised Bifidobacterium, and decreased Proteobacteria. Ex vivo work confirms SBI enhances SCFA production via specific gut microbes.

Gum arabic from Acacia arabica is a well-documented prebiotic with multiple studies confirming selective stimulation of beneficial gut bacteria. Human volunteer studies confirm dose-dependent bifidogenic effects. In vitro colon models show increased Bifidobacterium, reduced Clostridium, and enhanced short-chain fatty acid production.

Inulin is a plant-derived fructan fiber and one of the most robustly characterized prebiotics, with strong evidence from multiple human RCTs demonstrating selective stimulation of Bifidobacterium and Lactobacillus. It is ISAPP-designated as a prebiotic, and evidence supports improvements in stool frequency, gut barrier function, and microbiota-mediated metabolic outcomes.

Undigested sucrose reaching the colon is fermented by gut bacteria, shifting microbial community composition and generating excess gas. An enzyme blend containing invertase has been studied in vitro for its ability to pre-digest sucrose-containing FODMAPs, reducing colonic fermentation substrate available to the microbiome. Efficient proximal sucrose digestion by invertase therefore helps prevent dysbiotic fermentation patterns in the colon.

IMO functions as a prebiotic, selectively stimulating growth of Bifidobacterium, Lactobacillus, and Bacteroides in the colon. Clinical and in vitro studies consistently show increased beneficial bacteria counts and SCFA production. These microbiota shifts underpin most of IMO's downstream metabolic and gastrointestinal benefits.

A 2022 peer-reviewed review in Food Science & Nutrition (PubMed-indexed) documented jiaogulan's prebiotic potential, showing that its saponins and polysaccharides modulate gut microbiota composition. Animal studies show it increases beneficial bacteria (Akkermansia, Lactococcus) and reduces harmful strains in NAFLD and NASH models.

Jujube polysaccharides act as prebiotic substrates, modulating gut microbiota composition in animal models. Studies show increased Firmicutes/Lactobacillus abundance and decreased pathological dysbiosis in colitis-cancer and IBD mouse models. Polysaccharide fractions have been identified as promising prebiotic candidates in peer-reviewed research.

Kale supplementation in animal models increases gut bacterial diversity, raises the representation of beneficial Bacteroidales and Coriobacteriaceae, and lowers the Firmicutes:Bacteroidetes ratio. Kale's fiber and sulfoquinovose serve as prebiotics. A 2023 University of Maryland mouse study showed kale protected gut barrier integrity against acute DSS-induced inflammation.

Kefir is a fermented dairy beverage containing diverse probiotic bacteria and yeasts that collectively modulate gut microbiota. Multiple clinical studies show kefir consumption increases Lactobacillus and Actinobacteria in the gut, reduces pathogenic bacteria, and improves the Gut Microbiome Wellness Index in various populations.

Kelp polysaccharides—fucoidan, laminarin, and alginate—act as prebiotics, selectively promoting beneficial gut bacteria including Bifidobacterium and Akkermansia muciniphila. Human studies show alginate supplementation increases Bifidobacteria and short-chain fatty acid production. A fucoidan-rich kelp extract (SLE-F) showed microbiome-modulating effects in human trials with reduced gut permeability markers.

Kidney beans are rich in resistant starch, fermentable oligosaccharides, and fiber that serve as substrates for beneficial colonic bacteria. In vitro and preclinical studies document increased microbial diversity and short-chain fatty acid (especially butyrate) production. Clinical human evidence specific to kidney beans is limited, but broader pulse-microbiome evidence is robust.

Kombucha is a fermented tea beverage produced by a symbiotic culture of bacteria and yeast (SCOBY) that contains organic acids, polyphenols, and live microorganisms supporting gut microbiome health. A controlled clinical study (Scientific Reports, 2024) demonstrated kombucha consumption increased Ellagibacter and modified microbial metabolic pathways in healthy human gut microbiota.

AG modulates gut microbiota composition in colitis models, restoring diversity and favoring beneficial genera including Lactobacillus and Bacteroides. 16S rDNA sequencing in DSS-colitis mice showed AG reversed dysbiosis more effectively than free glutamine. AG also attenuates high-fat-diet-induced gut microbiota dysbiosis in NAFLD mouse models.

L-glutamine modulates gut microbiota composition through multiple mechanisms including reducing the Firmicutes-to-Bacteroidetes ratio, increasing secretory IgA, and limiting pathogenic bacterial translocation. Experimental and some clinical data support its role in reshaping the intestinal microbial environment.

L-Threonine is required for the synthesis of intestinal mucins, which form the mucus layer that shapes the gut microbiota habitat. Animal colitis studies show that diets enriched in threonine restore microbiota composition after disruption. Threonine deficiency has been shown to destabilize the gut microbial community. The mechanism is primarily indirect, via maintenance of the mucus matrix that supports beneficial microbial colonization.

Lactiplantibacillus plantarum is the updated taxonomic name for Lactobacillus plantarum, one of the most extensively studied gut-modulating probiotics with strong clinical evidence from multiple RCTs for gut microbiota composition improvement and IBS symptom management. See Lactobacillus plantarum entry for full evidence.

Lactobacillus species are among the most extensively studied and commercially used probiotics for gut microbiome health. Decades of clinical research across dozens of strains confirm their capacity to modulate gut microbial composition, inhibit pathogen colonization, enhance gut barrier function, and produce beneficial metabolites.

Lactobacillus acidophilus is one of the most studied probiotic species, with demonstrated effects on gut microbiota composition, colonization resistance against pathogens, and improvement of IBS and diarrheal conditions. The NCFM strain is the most extensively characterized and has strong clinical evidence for gut microbiome benefits.

Lactobacillus brevis is a heterofermentative lactic acid bacterium found in fermented foods and the human gut that demonstrates probiotic effects including gut microbiota modulation, GABA production, and inhibition of pathogenic bacteria. Several strains have been studied for gut health and immune modulation.

Lactobacillus delbrueckii subsp. bulgaricus is the classic yogurt starter culture organism that, alongside Streptococcus thermophilus, shapes the gut microbiome through fermented dairy consumption. Clinical evidence supports its role in improving gut microbial balance, reducing lactose intolerance symptoms, and contributing to beneficial microbiota changes in yogurt consumers.

Lactobacillus casei (now Lacticaseibacillus casei) is a clinically well-evidenced probiotic that modulates gut microbiota composition, reduces diarrhea, and improves microbial diversity. The Shirota strain (Yakult) is the most studied, with published RCTs confirming gut microbiome-modulating effects across multiple populations.

Lactobacillus fermentum is a heterofermentative lactic acid bacterium found in fermented foods and the human gut with demonstrated probiotic effects including gut microbiota modulation, antioxidant activity, and cholesterol reduction. Several strains have been evaluated in human clinical trials for gut health.

Lactobacillus gasseri is a commensal of the human gut and vaginal tract with documented probiotic effects on gut microbiota modulation, weight management, and pathogen exclusion. Human RCTs confirm gut microbiome-relevant effects including increased Lactobacillus and beneficial metabolic changes.

Lactobacillus helveticus is a thermophilic probiotic species used in Swiss and Italian cheese fermentation that produces bioactive peptides (lactotripeptides) with documented gut microbiome-modulating and immunomodulatory effects. Clinical studies confirm it modulates gut microbiota composition and reduces gut inflammation.

Lactobacillus paracasei (Lacticaseibacillus paracasei) is a commercially important probiotic species with multiple clinical studies demonstrating gut microbiota modulation, improved gut barrier function, and beneficial effects on IBS and atopic conditions through microbiome-mediated immune modulation.

Lactobacillus plantarum (Lactiplantibacillus plantarum) is one of the most versatile and widely studied probiotic species, with demonstrated effects on gut microbiota modulation, gut barrier reinforcement, and IBS symptom improvement in multiple RCTs. Its large genome enables extensive metabolic adaptation to the human gut environment.

Lactobacillus reuteri (Limosilactobacillus reuteri) is an autochthonous human gut commensal with documented probiotic effects including gut microbiota modulation, reuterin antimicrobial compound production, and clinical benefits in infantile colic, necrotizing enterocolitis prevention, and adult gut health across multiple RCTs.

Lactobacillus rhamnosus GG (LGG) is the world's most studied probiotic strain with the strongest clinical evidence base for gut microbiome health, including prevention of antibiotic-associated diarrhea, C. difficile prevention, IBS improvement, and gut microbiota modulation in infants, children, and adults.

Lactobacillus salivarius (Ligilactobacillus salivarius) is a native human oral and GI tract commensal that demonstrates probiotic effects including gut microbiota modulation, bacteriocin production, and improvements in IBS and intestinal permeability markers in clinical studies.

Lactococcus lactis is a lactic acid bacterium used in fermented dairy production that demonstrates gut microbiota-modulating effects and is being studied as a vehicle for delivery of therapeutic proteins to the gut. Clinical evidence supports its role in gut microbiome modulation and mucosal immune stimulation.

Lactoferrin is an iron-binding glycoprotein found in colostrum and milk that modulates gut microbiota by inhibiting pathogenic bacteria, promoting Bifidobacterium and Lactobacillus growth, and supporting intestinal barrier integrity. Human clinical studies in infants and adults confirm gut microbiome-relevant benefits.

L. edodes mycelia glucans modulate gut microbiota composition in animal and human studies. A clinical trial found that a shiitake beta-d-glucan-enriched extract altered the human intestinal microbiota profile. Animal data show increased microbiota diversity, elevated SCFA-producing bacteria, and prevention of dysbiosis.

Licorice root extracts display prebiotic-like activity in vitro and in animal models, increasing beneficial bacteria such as Bifidobacterium and Faecalibacterium prausnitzii while reducing pathobionts. A 2022 murine study showed LRE modulated gut microbiota composition in the context of candidiasis and colonic inflammation. Flavonoid polyphenols in licorice are the likely drivers via selective fermentation.

Dietary lignans require gut microbiota for conversion to the bioactive enterolignans enterodiol and enterolactone. This relationship is bidirectional: lignan-rich diets influence microbiome composition, while microbiome diversity determines enterolignan production capacity. Research identifies specific bacterial taxa responsible for enterolignan production, and lignan-rich oilseeds have been shown to modulate faecal microbiota in women.

Lion's Mane polysaccharides (HEPs) act as prebiotics, resisting digestion through the upper GI tract and fermenting in the colon to increase SCFA-producing bacteria and reduce pathobionts. Human fecal fermentation studies and a small human pilot study confirm microbiota-modulating effects.

Luteolin has been shown to enrich gut bacterial species diversity, reduce intestinal dysbiosis, and modulate the gut microbiome in preclinical NASH and metabolic syndrome models. It reduces plasma LPS and intestinal permeability, supporting a healthier gut microbial environment.

Macadamia nuts contain prebiotic fiber and polyphenols that support gut microbiome diversity. Systematic reviews of tree nut clinical trials (including macadamia) found evidence of beneficial gut microbiota modulation and short-chain fatty acid production. Macadamia oil cake (a by-product) was shown in animal studies to regulate intestinal microbiota composition.

Maitake's beta-glucan and polysaccharide content confers prebiotic properties, selectively feeding beneficial gut bacteria and promoting SCFA production in fermentation models. Animal studies demonstrate maitake polysaccharides modulate gut microbial composition and hepatic lipid-regulating gene expression. Direct human microbiome trials for maitake specifically are not yet published.

Human RCTs show mango consumption favorably modulates gut microbiome composition. A 12-week RCT in overweight/obese adults found increased microbial species evenness with mango intake versus a low-fat cookie control. Mango polyphenols, particularly gallotannins, are converted by gut bacteria into bioactive metabolites that promote beneficial species such as Lactobacillus plantarum.

Maqui berry polyphenols and anthocyanins act as prebiotics, being partially metabolized by gut microbiota into bioactive metabolites that may shift microbial composition toward beneficial strains. This is consistent with broader evidence for berry polyphenols. Direct human trials specifically on maqui's effect on gut microbiome composition are limited.

A PMC mouse study of NASH (advanced non-alcoholic steatohepatitis) showed mastic supplementation significantly improved gut microbiota diversity alongside reductions in liver ALT and hepatic steatosis. The active constituent masticadienonic acid has been shown to modulate gut microbiota composition in colitis mouse models. A 2021 RCT in IBD patients found mastic altered fecal metabolic profiles linked to immune response.

MCFAs, particularly caprylic (C8) and capric (C10) acids, demonstrate in vitro antimicrobial activity against pathogenic bacteria and Candida species, and animal/early human studies suggest MCT supplementation can reduce pathogenic gut microbes and decrease intestinal permeability. One study found dietary MCT reduced Candida colonization in preterm infant GI tracts.

Millet seed fiber and polyphenols modulate gut microbiota composition, increasing beneficial bacteria (Lactobacillus species, Lachnospiraceae) and SCFA production. Animal studies show millet polyphenols restore microbiome diversity in dysbiosis. Millet is also low-FODMAP and naturally gluten-free, making it well-tolerated in gut disorders.

Mogrosides pass to the colon largely intact and are metabolised by gut bacteria, with preclinical and in vitro studies showing promotion of beneficial bacteria including Bifidobacterium, Lactobacillus, and Akkermansia. A 2021 PMC-published in vitro study (PMC8495861) directly demonstrated that mogroside V modulates gut microbiota composition and short-chain fatty acid synthesis. Animal studies confirm shifts in microbiome diversity with enrichment of immune-related beneficial flora.

GML administered to broilers in feed studies modulated intestinal microbiota composition, improved intestinal barrier integrity, reduced inflammation, and enhanced antioxidant capacity. Human data are limited; oral GML's selective antibacterial activity (targeting pathogens while relatively sparing beneficial bacteria) has been proposed but not formally confirmed in human gut microbiome studies.

Morus alba leaf and fruit polysaccharides and polyphenols modulate gut microbiota composition in preclinical models, improving beneficial bacteria populations and short-chain fatty acid production. This mechanism links Morus to improvements in insulin resistance, obesity, and inflammation via the gut-microbiota axis, with mechanistic human data emerging.

Mucin glycans serve as a selective nutritional substrate for specific gut bacteria, meeting the formal definition of a prebiotic. In vitro and preclinical research shows mucin supplementation reshapes microbial composition, enriching beneficial Lactobacillus species and promoting polyamine production that supports epithelial barrier function. The human body's continuous mucus desquamation has been described as producing its own prebiotic.

TC's polyphenol-rich composition selectively inhibits pathogenic intestinal bacteria while research on Triphala (the TC-containing formula) demonstrates prebiotic-like modulation of obese fecal microbiome in a gut model study. TC also shows activity against intestinal pathogens including Salmonella and E. coli.

Naringin undergoes extensive microbial metabolism in the human gut, and bidirectionally modulates gut microbiota composition. In high-fat diet mouse models, naringin intervention increased beneficial bacteria and reduced harmful bacterial genera while attenuating dysbiosis-linked NAFLD. Gut microbial metabolism of naringin to naringenin has been confirmed in human fecal incubation studies.

Human and animal studies demonstrate that nopal fiber modulates gut microbiota composition, increasing beneficial taxa and reducing markers of dysbiosis and metabolic endotoxemia. A 2022 human study in women with obesity found that dietary nopal intervention improved gut microbiota diversity. Animal studies show nopal reduces endotoxemia by modifying the cecal and colonic microbiota in high-fat-fed rats, increasing colonic occludin protein to reduce gut permeability.

Oat β-glucan acts as a prebiotic, increasing counts of beneficial bacteria (Lactobacillus, Bifidobacterium), short-chain fatty acid production, and gut permeability markers in clinical studies. A systematic review of 84 studies confirmed oat intake increased total bacterial count and SCFA concentrations.

Okra's pectin and mucilage polysaccharides function as prebiotics, feeding beneficial colonic bacteria and stimulating short-chain fatty acid production. A preclinical study (2022, PubMed 36481254) demonstrated okra pectic polysaccharide modulated gut microbiota in mice with acute liver injury, promoting SCFA secretion. Human evidence linking okra to specific microbiome changes remains limited to mechanistic inference.

Olive oil phenolic compounds selectively promote beneficial gut bacteria, increase alpha diversity, and enhance short-chain fatty acid production. A 2026 prospective cohort of 656 older adults linked virgin olive oil consumption to beneficial gut microbiota composition and improved cognitive outcomes. EVOO also strengthens intestinal barrier integrity.

Onion contains fructooligosaccharides (FOS) and inulin that function as prebiotics, selectively promoting beneficial gut bacteria. A 2025 PMC study demonstrated that onion extracts alter gut microbial structure and promote production of short-chain fatty acids (SCFAs) and beneficial indole metabolites. Onion extract also enhances growth of beneficial probiotics.

Ophiopogon root polysaccharides (OJPS) and oligosaccharides (OJO) have been shown in animal studies to modulate gut microbiota composition, restore Firmicutes/Bacteroidota balance, and improve intestinal barrier integrity. A 2025 Frontiers in Pharmacology study demonstrated that OJO treatment in T2DM rats significantly altered gut microbial communities alongside metabolic improvements. OJPS is classified as acting on gut microbiota via prebiotic mechanisms.

Oregano oil's carvacrol and thymol selectively modulate gut microbiota by suppressing pathogenic bacteria while evidence for sparing beneficial species is emerging. The dual antimicrobial and anti-inflammatory properties affect microbial balance in the gastrointestinal tract. Extended use has been reported to reduce Lactobacillus and Bifidobacterium populations, underscoring a complex and dose-dependent interaction.

Berberine from Oregon grape modulates gut microbiota composition, increasing SCFA-producing bacteria and altering bile acid metabolism. Studies in preclinical models show berberine can selectively inhibit dysbiotic bacteria and reshape the microbiota-gut-brain axis. A BMC Microbiology study confirmed berberine alters microbial function through bile acid modulation.

Rice bran dietary fiber from Oryza sativa modulates gut microbiome composition, enriching beneficial Bacteroides and inhibiting pathogenic bacteria in in vitro fermentation and animal models. Human infant RCT data also show shifts in microbiota signatures following rice bran supplementation.

Bile acids are potent modulators of gut microbial ecology, exerting direct antimicrobial activity and shaping community composition through FXR signaling. Primary bile acids from ox bile supplements alter the ratio of primary to secondary bile acids in the intestinal lumen, which in turn influences the relative abundance of bile-tolerant vs. bile-sensitive bacterial taxa. The gut microbiota reciprocally biotransforms bile acids into secondary forms, creating a bidirectional axis with metabolic and immunological consequences.

Oyster mushroom β-glucans and polysaccharides act as prebiotics, selectively stimulating beneficial gut bacteria and short-chain fatty acid production. In vitro fermentation studies with human gut microbiota demonstrate prebiotic activity comparable to established prebiotics such as FOS and inulin. A 2025 RCT showed that individual GLP-1 responses to oyster mushroom powder are shaped by baseline gut microbiota composition.

Preclinical research shows POA administration favorably shifts gut microbiota composition in high-fat diet models, including restoration of Akkermansia abundance and reduction of the Firmicutes/Bacteroidetes ratio. No dedicated human RCTs on POA and gut microbiome have been published.

Pea fiber acts as a prebiotic substrate, increasing gut microbial diversity and abundance of beneficial bacteria. Animal studies show a 10% pea fiber diet significantly improved colonic microbiota composition and diversity. Pea components promote SCFA production, which supports gut barrier integrity and systemic metabolic health.

Peanut fibre acts as a prebiotic, and peanut-derived resveratrol has been shown to modulate gut microbiota composition in preclinical models by enriching Lactobacillus and Bifidobacterium. An ongoing RCT (ClinicalTrials.gov NCT06867198) is directly studying peanuts' effects on gut microbiota. Peanut polyphenols also support gut barrier integrity.

Pear's soluble dietary fiber and polyphenols act as prebiotics, selectively enriching beneficial gut bacteria. Animal research with pear pomace soluble dietary fiber (PP-SDF) showed significant increases in Akkermansia, Bifidobacterium, and Lachnospiraceae, supporting microbiome diversity. In vitro fermentation studies confirm pear cultivars stimulate butyrate-producing species in the human gut.

Pectin is a soluble dietary fiber from fruit cell walls with well-documented prebiotic effects, selectively promoting Bifidobacterium, Akkermansia muciniphila, and Bacteroides species in the gut. It generates acetate and propionate upon fermentation and supports gut barrier function via mucosal immune effects.

Pediococcus acidilactici is a homofermentative lactic acid bacterium used in probiotic formulations with demonstrated gut microbiota modulation capacity. It produces pediocin bacteriocins with activity against Listeria and Clostridium, and clinical studies support its role in gut microbiome composition improvement.

Pediococcus pentosaceus is a lactic acid bacterium with probiotic activity that modulates gut microbiota composition, produces bacteriocins active against pathogens, and has been evaluated in studies showing gut microbiome-relevant changes including reduction of pathogenic bacteria and improvement in SCFA profiles.

Perilla seed oil and seed residue extract demonstrate prebiotic-like effects in animal models, increasing abundance of beneficial gut bacteria (Lactobacillus, Akkermansia, Bacteroides fragilis) and reducing pro-inflammatory pathobionts. A 2025 PMC study specifically demonstrated perilla extract restored gut microbial diversity in diabetic rats toward healthy control profiles.

Psyllium (Plantago ovata) acts as a prebiotic, supporting beneficial gut bacteria and increasing production of short-chain fatty acids (butyrate, propionate). This favorably modulates the gut microbiome composition and is supported by clinical and experimental data.

Plantago polysaccharides (particularly psyllium arabinoxylan) regulate gut microbiota composition in clinical studies. Psyllium increases SCFA-producing bacteria (Faecalibacterium, Lachnospira, Phascolarctobacterium) and modulates Bifidobacterium in a baseline-dependent manner in human studies. These microbiome changes support colonic health, immune modulation, and intestinal barrier integrity.

Platycodon polysaccharides have been shown to modulate gut microbiota composition in animal models, increasing beneficial bacteria such as Akkermansia, improving intestinal barrier integrity, and reducing dysbiosis associated with high-fat diet and immunosuppression. These effects are linked to broader metabolic and immune outcomes.

A 2023 double-blind RCT found pomegranate extract (Pomella 250 mg) altered gut microbiome composition and produced urolithins in healthy adults. Pomegranate ellagitannins are metabolized by gut microbiota into urolithins, which have health-promoting effects, and the prebiotic activity supports Lactobacillus and Bifidobacteria genera.

Pomelo by-products including peel pectins, dietary fibers, and flavonoids selectively modulate gut microbiota by promoting beneficial genera and enhancing short-chain fatty acid (SCFA) production. Pomelo peel polysaccharides have been shown in mouse models to alleviate ulcerative colitis by enriching Blautia and Bacteroides acidifaciens. Pomelo's prebiotic fiber supports balanced gut microbial communities.

Propionate is both a product of and a modulator of the gut microbiome. It is produced by Bacteroidetes, Firmicutes, and specific genera including Prevotella and Blautia through fermentation of dietary fiber. Changes in propionate production correlate with microbiome composition shifts in disease states including IBD, IBS, and metabolic conditions. Dietary propionate exposure at high levels has been shown to alter microbial community structure.

A 12-month RCT in postmenopausal women (Food & Function, 2022) found prune supplementation significantly enriched Lachnospiraceae—bacteria associated with reduced inflammatory markers and gut barrier integrity. Prune fiber and polyphenols also increase Bifidobacterium populations in healthy adults. Microbiome modulation is now considered a key mechanism linking prune consumption to bone, immune, and cardiovascular benefits.

Psyllium husk is a soluble fiber from Plantago ovata seeds with documented prebiotic effects, increasing Bifidobacterium and Lactobacillus while supporting SCFA production. Multiple human RCTs confirm its gut microbiota-modulating effects, and it is used as both a laxative and prebiotic dietary fiber.

Quercetin is a flavonol polyphenol that modulates gut microbiota composition through probiotic-like promotion of beneficial bacterial species, inhibition of pathogenic bacteria, and enhancement of gut barrier tight junctions. Multiple preclinical and emerging clinical studies confirm bidirectional gut microbiota–quercetin interactions.

Preclinical evidence from 19 studies reviewed in a 2025 scoping review found quinoa-derived bioactive peptides enhanced beneficial gut genera in 83% of studies and increased alpha diversity in 67%, with consistent butyrate production enhancement. Quinoa polysaccharides act as prebiotics promoting Bifidobacteria growth. In vitro fermentation with human fecal microbiota confirmed the prebiotic effect of quinoa and quinoa polysaccharides.

In vitro and animal research shows that glucosinolate-enriched radish modulates intestinal microbiota composition in obese subjects' gut conditions, promoting beneficial bacterial growth. A radish seed glucosinolate extract in high-fat diet mice favorably shifted gut microbiota and fecal metabolomes. These are preclinical findings with no human trials yet published.

Red raspberry fruit provides dietary fiber and polyphenols—including ellagitannins and anthocyanins—that modulate gut microbiome composition in preclinical and human studies. A randomized 4-week crossover trial in prediabetic subjects found that 1 cup/day of raspberries with or without FOS supplementation produced distinctive metagenomic biomarker shifts. Raspberry polyphenols also show prebiotic-like effects, supporting beneficial short-chain fatty acid production. Interindividual variability in responses has been documented.

Reishi beta-glucan polysaccharides act as prebiotics, selectively feeding beneficial gut bacteria and modulating the Firmicutes:Bacteroidetes ratio. A well-cited mouse study (Chang et al.) showed reishi reversed high-fat-diet-induced gut dysbiosis and obesity-related metabolic disruption. A PMC review (2022) confirmed strong evidence for prebiotic activity. Direct human RCT data are limited but mechanistic and animal evidence is substantial.

Resveratrol is a stilbene polyphenol with well-documented gut microbiota-modulating effects, including promoting Lactobacillus and Bifidobacterium growth, inhibiting pathogenic E. coli, and stimulating SCFA (butyrate) production. A systematic review of its microbiome effects and multiple mechanistic studies confirm its prebiotic-like activity.

A double-blind RCT in middle-aged adults demonstrated that rhubarb root extract modulated gut microbiome composition alongside constipation relief. Animal studies using 16S rRNA sequencing confirmed increases in beneficial bacterial taxa and decreases in pathogens following rhubarb treatment.

Preclinical studies demonstrate that rosmarinic acid modulates gut microbiota composition, increasing short-chain fatty acid (SCFA)-producing bacteria while reducing LPS-producing pathobionts. In allergic asthma models, RA's anti-asthmatic effects were partially mediated through the gut-lung axis via microbiome modulation. RA's low oral bioavailability means it interacts substantially with colonic microbiota.

Rye's fermentable fibers (arabinoxylans, fructans, resistant starch) serve as prebiotic substrates that are fermented by colonic bacteria to SCFAs, supporting epithelial integrity and beneficial microbial populations. Human and in vitro studies demonstrate increased Lactobacillus and Bifidobacterium and elevated butyrate production following rye fermentation. A 6-week RCT showed rye affected fecal butyrate concentrations in overweight adults.

Saccharomyces boulardii is the most studied probiotic yeast, validated in over 90 randomized clinical trials for gut microbiome modulation, prevention of antibiotic-associated diarrhea, and treatment of C. difficile-associated disease. ESPGHAN guidelines recommend it for acute infectious diarrhea, and it significantly modulates gut microbial composition.

A randomized, double-blind, placebo-controlled study in 28 obese women found schisandra chinensis fruit (SCF) modulated gut microbiota composition in association with improvements in metabolic markers over 12 weeks. Schisandra polysaccharide studies in AD rat models also show significant beneficial remodeling of gut microbiota.

A 12-week RCT in 28 women demonstrated that 6.7 g/day of Schisandra improved gut microbiota diversity alongside metabolic markers. Preclinical studies in Alzheimer's rat models show schisandrin corrects gut microbiota structural disorder and increases the abundance of beneficial bacteria.

Poria cocos sclerotium polysaccharides act as prebiotics in vitro and in animal studies, selectively increasing beneficial bacteria (Lactobacillus, Bifidobacterium) and boosting short-chain fatty acid production while reducing pathogenic taxa. Human clinical studies in IBS patients also report modulation of gut microbiota abundance.

SDG is metabolized by gut bacteria into enterodiol and enterolactone, and in turn modulates microbial diversity and composition. Animal studies show SDG alters abundance of inflammation-related gut bacteria and increases short-chain fatty acid (SCFA) production. The gut microbiome is both a prerequisite for SDG bioactivation and a target of its prebiotic-like effects.

Animal studies using 16S rRNA gene sequencing have shown that Massa Medicata Fermentata modulates intestinal microbiota composition in dyspepsia and spleen-deficiency models, improving α- and β-diversity. Prebiotic and probiotic components produced during fermentation are mechanistically implicated.

Shiitake polysaccharides act as prebiotics, selectively feeding beneficial gut bacteria. A PubMed-indexed rodent study showed L. edodes supplementation increased microbiome species richness and raised abundance of Akkermansia, Lactococcus, and Bacteroides. Polysaccharides also increase short-chain fatty acid production and improve intestinal mucosal barrier integrity.

Z. bungeanum amides have been shown in a rodent NAFLD model to modulate gut microbiota composition and increase short-chain fatty acid production. Hydroxy-α-sanshool has also been associated with favourable shifts in gut metabolites and microbial diversity in insulin-resistant mice. Evidence is currently preclinical.

Slippery elm bark polysaccharides and arabinogalactan-type fibers are documented as having prebiotic potential, feeding Lactobacillus and Bifidobacterium species. A 2018 review in the Journal of Alternative and Complementary Medicine (Peterson et al.) specifically evaluated slippery elm among herbs with prebiotic potential for digestive health. A 2020 clinical study also documented improved microbial profiles in participants taking a slippery elm-containing formula.

The gut microbiome bidirectionally interacts with soy isoflavones: specific bacteria metabolize daidzein into S-equol, dramatically amplifying isoflavone bioactivity. Soy fiber also serves as a prebiotic. Equol-producer status, determined by microbiome composition, is a key modifier of all soy health outcomes.

The gut microbiome extensively modulates soy isoflavone bioactivity, converting daidzein to the more potent equol, which in turn alters cardiovascular, hormonal, and metabolic outcomes. Soy food intake has been associated with changes in gut metabolome and microbiome composition. Soy's dietary fiber content acts as a prebiotic substrate, and the relationship between soy and gut microbiota is bidirectional.

Spinach fiber (both soluble and insoluble) acts as a prebiotic substrate for colonic bacteria. Preclinical data show spinach thylakoids modulate gut microbiota composition and decrease food intake. Spinach's polyphenols and chlorophyll also influence microbial diversity.

Spirulina (Arthrospira platensis) is a blue-green microalgae used as a nutritional supplement with documented gut microbiota-modulating effects, including promotion of Lactobacillus and inhibition of pathogenic bacteria. Several preclinical and early human studies support its prebiotic-like activity and gut microbiome modulation.

The metabolism of steviol glycosides depends entirely on gut microbiota, which hydrolyze glycosides to absorbable steviol. Animal and in vitro studies show mixed effects on microbiome composition; a PMC 2022 systematic review found potential benefit on alpha diversity. Human batch fermentation studies found no significant changes in major bacterial groups. A 2024 human study found no noticeable changes in gut microbiota from stevia use.

Stigmasterol modulates gut microbiota composition in multiple animal models, increasing beneficial Lactobacillus species, reversing high-fat diet-induced dysbiosis, and enhancing SCFA (particularly butyrate) production. Fecal microbiota transplant experiments confirm that gut microbiota mediates some of stigmasterol's systemic effects.

Strawberry ellagitannins are metabolized by colonic microbiota into bioactive urolithins, a bidirectional relationship where gut bacteria convert strawberry polyphenols into systemic metabolites and strawberry phytochemicals in turn modulate microbial composition. A human study found California strawberry consumption increased gut microorganisms associated with lean body weight and longevity. Gut metabolism of strawberry-derived metabolites mediates their anti-vascular inflammation effects.

Streptococcus thermophilus is a key yogurt starter culture organism and EFSA Qualified Presumption of Safety (QPS) organism with well-documented effects on gut microbiota, specifically increasing Streptococcus and Lactobacillus in the gut, producing lactase to reduce lactose intolerance symptoms, and modulating mucosal immune responses.

Sulforaphane modulates gut microbial composition, reverses dysbiosis, and increases short-chain fatty acid production in preclinical models. Clinical data in chronic kidney disease patients show significant gut microbial network remodeling after SFN supplementation. It also protects colonocyte function and tight junction integrity.

In HFD-fed mice, THIAA (META060) reduced metabolic endotoxemia, decreased portal plasma LPS, and was associated with improved gut barrier markers, including restoration of tight junction proteins ZO-1 and occludin. These effects indicate indirect modulation of gut microbiome-driven systemic inflammation. This study provides mechanistic evidence linking THIAA to gut microbiome-related outcomes.

Tributyrin modulates gut microbial composition, enriching beneficial taxa such as Bifidobacterium, Bacteroides fragilis, and Alistipes while countering dysbiosis. In vitro and animal studies show tributyrin-driven beta-diversity shifts, particularly in the proximal colon. It supports endogenous butyrate-producing bacteria through an epigenetic-metabolic feedback loop.

Clinical and in-vitro data show Triphala's polyphenols modulate gut microbiota, promoting Akkermansia muciniphila and historically Bifidobacteria and Lactobacillus while inhibiting pathogenic microbes. A 2025 SHIME model study confirmed increased antioxidant potential and shifts in microbial metabolite profiles. A human RCT (n=adults) showed personalized microbiome responses.

Curcumin modulates gut microbiota composition, promoting beneficial bacteria while suppressing pathogenic strains, and enhances intestinal barrier function. A 2026 clinical trial in IBD patients using 16S rRNA sequencing found transient microbiota shifts with curcumin. Preclinical and emerging clinical evidence support a meaningful gut microbiome interaction.

UA is itself a product of gut microbial metabolism of ellagitannins and its production varies greatly by individual microbiome composition. In gut models, UA strengthens intestinal barrier function by upregulating epithelial tight junction proteins via aryl hydrocarbon receptor (AhR)-Nrf2 pathways. Only approximately one-third of people have the microbiota capable of efficiently converting ellagitannins to UA.

A PMC-indexed animal study found vanillin significantly improved gut microbiome composition in obese mice, increasing Bacteroidetes richness and short-chain fatty acid (SCFA) production while reducing LPS-producing and H2S-producing bacteria. Evidence is from animal models only; no human microbiome trials have been conducted.

Wheat bran and whole wheat are established prebiotic sources, with arabinoxylan and fructan components selectively promoting Bifidobacterium, Roseburia, Bacteroides/Prevotella, and butyrate-producing bacteria. A systematic review of intact cereal grain fiber RCTs confirmed significant shifts in gut microbiota composition from wheat bran. Fermentation produces SCFAs (butyrate, acetate, propionate), which benefit colonic epithelial health.

Wheat germ fiber and associated bran fractions support gut microbiome diversity by acting as substrates for beneficial bacteria. Human and ex vivo studies demonstrate that wheat grain fractions increase Bifidobacterium and butyrate-producing species like Roseburia. Greater whole grain and dietary fiber intake is associated with higher gut microbial diversity.

Whey proteins including beta-lactoglobulin, alpha-lactalbumin, glycomacropeptide, and lactoferrin exhibit prebiotic-like and antimicrobial properties that can favorably shift gut microbial composition. Evidence from in vitro, in vivo, and clinical studies shows whey can enhance Bifidobacterium and Lactobacillus while suppressing harmful bacteria. Whey supplementation has also been linked to increased short-chain fatty acid production and strengthened mucosal barrier integrity.

Xylanase hydrolyzes dietary xylans into xylooligosaccharides (XOS), which selectively promote the growth of beneficial gut bacteria such as Bifidobacterium and Bacteroides. A 2025 Food Chemistry study demonstrated that a GH11 xylanase from Trichoderma longibrachiatum produced prebiotic XOS under simulated gastrointestinal conditions. XOS fermentation by colonic microbiota generates short-chain fatty acids (SCFAs) that further support microbial homeostasis. Human RCT data on XOS supplementation confirms bifidogenic and microbiome-modulating effects.

Xylooligosaccharides (XOS) are oligosaccharides derived from xylan with documented prebiotic activity, selectively stimulating Bifidobacterium growth and SCFA production including butyrate. Multiple in vitro fermentation studies and human trials confirm their gut microbiota-modulating effects as an emerging prebiotic.

Beta-glucan derived from S. cerevisiae cell walls acts as a prebiotic, selectively promoting growth of beneficial Bifidobacterium and Lactobacillus species in the gut. Mannan-oligosaccharides (MOS) from yeast cell walls similarly support beneficial microbiota. In vitro and animal studies are robust; human evidence is emerging.

Preclinical evidence and early clinical data indicate zeolite clinoptilolite can beneficially modulate gut microbial composition. Animal studies show reductions in pathogenic Enterobacteriaceae and increases in beneficial Lactobacillus species. A placebo-controlled IBS-D RCT reported improvements in microbial diversity versus placebo. Human data remain preliminary and largely supported by preclinical work.

Bael's immunomodulatory and antimicrobial properties are proposed to support a healthy gut microbiome balance, and traditional Ayurvedic use of bael for GI dysbiosis conditions (dysentery, diarrhea, and fermentative dyspepsia) aligns with microbiome health concepts. Direct microbiome studies are not available, but the plant's activity against gut pathogens is documented.

Boswellia's anti-inflammatory and intestinal barrier-protective effects — reducing NF-κB signalling, preserving tight junction integrity, and reducing oxidative stress in the gut — create an environment relevant to microbiome health. IBD research supports mucosal healing. Direct prebiotic or microbiome-modulating human clinical trial evidence is lacking.